Loading
Life sciences · Journal article
Healthcare · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, requiring coordinated long-term management of cardiovascular risk factors, complex pharmacotherapy, and continuity of care across healthcare settings. Community pharmacists are well-placed to support ambulatory cardiovascular care; however, their contribution often remains insufficiently integrated into cardiovascular care pathways, limiting continuity, information exchange, and coordinated medication management across community, primary, and specialist care. This study aimed to establish the scientific basis for the development of an Integrated Ambulatory Pharmaceutical Follow-Up Programme in Cardiology by synthesising the available evidence on pharmacist-led cardiovascular care. Methods: An evidence-informed narrative synthesis was conducted using targeted searches of PubMed/MEDLINE, Scopus, and Web of Science, complemented by manual screening of reference lists. Priority was given to systematic reviews, meta-analyses, randomised controlled trials, and high-quality observational studies addressing pharmacist-led interventions in cardiovascular risk management, heart failure, transitions of care, cardiac rehabilitation, and integrated pharmaceutical care. Evidence was mapped across clinical outcomes, care processes, professional roles, and implementation requirements and subsequently translated into the components of the proposed integrated ambulatory care framework. Results: The available evidence consistently indicates that pharmacist-led interventions improve cardiovascular risk factor control, medication adherence, pharmacotherapy optimisation, and patient-reported outcomes. Community pharmacies provide accessible and effective settings for cardiovascular risk screening, chronic disease monitoring, and structured follow-up. In heart failure, pharmacist involvement supports optimisation of guideline-directed medical therapy, while during care transitions it contributes to the identification and reduction in medication-related problems. In cardiac rehabilitation and secondary prevention, pharmacist-led care supports medication optimisation, adherence, and cardiovascular risk-factor management. Overall, the available evidence supports the integration of community pharmacists into multidisciplinary ambulatory cardiovascular care pathways and provides the evidence base for the proposed conceptual framework. Conclusions: The proposed Integrated Ambulatory Pharmaceutical Follow-Up Programme in Cardiology provides an evidence-informed conceptual framework to support the structured integration of community pharmacists into ambulatory cardiovascular care. Its implementation has the potential to strengthen continuity of care, optimise pharmacotherapy, and support improved cardiovascular outcomes when supported by collaborative practice models, interoperable health information systems, and appropriate organisational frameworks.